Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D92OCI
|
|||
| Drug Name |
Toripalimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Demodex blepharitis [ICD-11: 1G07] | Approved in China | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Approved in China | [1] | ||
| Nasopharyngeal cancer [ICD-11: 2B6B] | Approved in China | [1] | ||
| Urothelial carcinoma [ICD-11: 2C92.0] | Approved in China | [1] | ||
| Esophageal squamous cell carcinoma [ICD-11: 2E60.1; ICD-10: D00.1; ICD-9: 150] | Phase 3 | [2] | ||
| Company |
Coherus Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. | |||
| REF 2 | ClinicalTrials.gov (NCT03829969) A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy. U.S.National Institutes of Health. | |||
| REF 3 | Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.